SCHEMBL5145299

SCHEMBL5145299

CN(C)CCNC(=O)COc1ccc2c(c1)CC(N(Cc1ccccc1)C[C@H](O)COc1ccccc1)CCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
CASP2 P42575 1/20 0.41
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
TAOK1 Q7L7X3 2/20 0.39
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
LGALS1 P09382 1/20 0.37
TAOK3 Q9H2K8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143801 0.88 TAOK1 (0.45) PRMT5WDR77LMNATAOK1SMN1; SMN2
SCHEMBL7753292 0.85 PRMT5 (0.43) PRMT5WDR77LMNAHTTMEN1
SCHEMBL5144158 0.85 PRMT5 (0.44) PRMT5WDR77LMNAHTTMEN1
SCHEMBL5142060 0.84 ADRB3 (0.48) PRMT5WDR77CYP2D6MEN1KMT2A
Hydrochloric Acid SCHEMBL7565474 0.83 ADRB3 (0.47) PRMT5WDR77CYP2D6MEN1KMT2A
SCHEMBL5143809 0.83 CTSD (0.38) PRMT5WDR77SMN1; SMN2MEN1KMT2A
SCHEMBL5143628 0.83 PRMT5 (0.45) PRMT5WDR77LMNAMEN1KMT2A
SCHEMBL5143959 0.82 ALDH1A1 (0.48) PRMT5WDR77MEN1KMT2AMAPT
SCHEMBL5144084 0.82 PRMT5 (0.46) PRMT5WDR77CYP2D6MAPTTSHR
Hydrochloric Acid SCHEMBL5145521 0.82 ADRB3 (0.47) CASP2LMNACYP3A4CYP2D6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217706-B2 Propanolamine derivatives ASTELLAS PHARMA INC. (JP) 2007-05-15 US disclosed
EP-1382333-A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-21 EP disclosed
US-6495546-B1 SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
US-20020120148-A1 Propanolamine derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120148-A1 Propanolamine derivatives AMY2A, PNMT, PNLIP PRMT5 849/4885WDR77 2347/4885CASP2 3621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.